1. Abubakr Y, Eng C, Wong L, Pautret V, Scheithauer W, Maurel J et al. (2006). Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC). J Clin Oncol 24 (18S): Abstract 3556.
2. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D et al. (2004). Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. A model to predict long-term survival. Ann Surg 240: 644–658.
3. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK et al. (2001). High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61: 4750–4755.
4. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC . (2006). Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55: 657–670.
5. Andre T, Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, Humblet Y et al. (2007). Phase II study with cetuximab plus FOLFOX-4 in first-line setting for epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Final results. Proc ASCO GI: abstract 334.